Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Ottawa

$17,500.00

Innovating a bioengineered S2 cell line platform for cost-effective large-scale production of oncolytic virotherapies.

EF 2023-24

Résumé
Cancer-killing or oncolytic virus (OV) therapies represent a novel class of cancer immunotherapies that have garnered significant interest due to their versatility and multi-mechanistic anti-cancer activity. Affordable mass production of such platforms is essential to delivering innovative therapies to cancer patients, however, manufacturing of OVs is limited by inefficient and resource-intense manufacturing processes. For example, oncolytic rhabdovirus (ORV) products are currently being produced in African green monkey kidney cells (Vero cells), which yield 20,000 plaque forming units (PFU) per infected cell. The Ottawa Biotherapeutics Manufacturing Core facility (BMC) can produce an average of 2E14 PFU per manufacturing run over a 6-week process at a cost of over 2 million dollars. While these numbers are adequate for early clinical studies, future applications are dependent on improving manufacturing yields while reducing production costs. Herein, we propose the validation of a new and more efficient bioengineered cell line to produce ORV vectors based on fruit fly (Drosophila melanogaster) Schneider 2 (S2) cell system. Therefore, I aim to develop and characterize a highly productive and scalable S2 cell system, which will lead to the highest quality of virus-based products at the lowest cost. An RNAi suppressor will be encoded within the cell line to block the S2 cell RNAi antiviral pathway. I will then compare the viral output of the modified cells to the standard process of ORV production. If the cell line proves favourable for ORV manufacturing, we will investigate the modification of the glycosylation patterns to resemble those of human cells. These modifications were previously demonstrated to increase viral titres and safety, respectively.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
507049
Name
Jang Samantha M
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Innovating a bioengineered S2 cell line platform for cost-effective large-scale production of oncolytic virotherapies.
Programtype2
Studentship Programs
Orgnameinp2
University of Ottawa
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cancer; Glycosylation; Manufacturing; Nodamura Virus B2 Protein; Rhabdovirus; Rna Inhibition; Schneider 2 Cells
Abstract
Cancer-killing or oncolytic virus (OV) therapies represent a novel class of cancer immunotherapies that have garnered significant interest due to their versatility and multi-mechanistic anti-cancer activity. Affordable mass production of such platforms is essential to delivering innovative therapies to cancer patients, however, manufacturing of OVs is limited by inefficient and resource-intense manufacturing processes. For example, oncolytic rhabdovirus (ORV) products are currently being produced in African green monkey kidney cells (Vero cells), which yield 20,000 plaque forming units (PFU) per infected cell. The Ottawa Biotherapeutics Manufacturing Core facility (BMC) can produce an average of 2E14 PFU per manufacturing run over a 6-week process at a cost of over 2 million dollars. While these numbers are adequate for early clinical studies, future applications are dependent on improving manufacturing yields while reducing production costs. Herein, we propose the validation of a new and more efficient bioengineered cell line to produce ORV vectors based on fruit fly (Drosophila melanogaster) Schneider 2 (S2) cell system. Therefore, I aim to develop and characterize a highly productive and scalable S2 cell system, which will lead to the highest quality of virus-based products at the lowest cost. An RNAi suppressor will be encoded within the cell line to block the S2 cell RNAi antiviral pathway. I will then compare the viral output of the modified cells to the standard process of ORV production. If the cell line proves favourable for ORV manufacturing, we will investigate the modification of the glycosylation patterns to resemble those of human cells. These modifications were previously demonstrated to increase viral titres and safety, respectively.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jang, Samantha M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~